COMBINATION EFFECT OF LULICONAZOLE AND CLOBETASOL FOR TREATMENT OF SKIN AILMENTS

Authors

  • DEEPAK PRASHAR Department of Pharmacy, Green Hills Pharmacy College, Solan (HP) India
  • VIVEK KUMAR Department of Pharmacy, LR Institute of Pharmacy, Solan (HP) India
  • KHUSHBOO JASRA Department of Pharmacy, Green Hills Pharmacy College, Solan (HP) India

DOI:

https://doi.org/10.22159/ijcpr.2022v14i2.1949

Keywords:

Antifungal agent, Clobetasol propionate, Glucocorticosteroids, Luliconazole, Derivative spectroscopic method

Abstract

Objective: The new combination for Luliconazole and Clobetasol Propionate was approved for the treatment of a variety of skin disease. The main objective of this research is development and validation of novel, simple, fast and responsive derivative spectroscopic process for simultaneous estimation of newly approved combination Luliconazole (LLZ) and Clobetasol Propionate (CLP).

Methods: Here in this first derivative spectroscopic method, the absorbance of LLZ and CLP was taken at 312 nm (ZCP of CLP) and 249 nm (ZCP of LLZ), respectively. Establishment of linearity was in a concentration varies from 10-50 µg/ml for Luliconazole and 5-25µg/ml for Clobetasole Propionate.

Results: From the method developed above the R2 value observed for LLZ and CLP is 0.9961. Statistical validation of accuracy and reproducibility was done for planned procedure with the help of recovery studies. The mean % recovery of Luliconazole and Clobetasol Propionate was found to be 99.45 % and 99.43%, respectively. For LLZ the Limit of detection is 0.9988 µg/ml and limit of quantification is 0.0009µg/ml and for CLP the Limit of detection is0.0164µg/ml and limit of quantification 0.0027µg/ml.

Conclusion: From research work the method development was done and shows fast, precise, exact and easy accessible laboratory procedure for routine evaluation of combination drugs.

Downloads

Download data is not yet available.

References

Saunders J, Maki K, Koski R, Nybo SE. Tavaborole, efinaconazole, and luliconazole: three new antimycotic agents for the treatment of dermatophytic fungi. J Pharm Pract. 2017;30(6):621-30. doi: 10.1177/0897190016660487, PMID 27488125.

Khanna D, Bharti S. Luliconazole for the treatment of fungal infections: an evidence-based review. Core Evid. 2014;9:113-24. doi: 10.2147/CE.S49629, PMID 25285056.

Pels R, Sterry W, Lademann J. Clobetasol propionate-where, when, why? Drugs Today (Barc). 2008;44(7):547-57. doi: 10.1358/dot.2008.44.7.1122221, PMID 18806904.

Lorenz B, Kaufman RH, Kutzner SK, Lichen Sclerosus. Therapy with clobetasol propionate. J Reprod Med. 1998;43(9):790-4. PMID 9777618.

Gagliardi L, De Orsi D, Giudice MRD, Gatta F, Porrà R, Chimenti P, Tonelli D. Development of a tandem thin-layer chromatography-high-performance liquid chromatography method for the identification and determination of corticosteroids in cosmetic products. Anal Chim Acta. 2002;457(2):187-98. doi: 10.1016/S0003-2670(02)00017-X.

Jakasaniya M, Shah J, Maheshwari D. Simultaneous estimation of clobetasol propionate and fusidic acid in cream dosage form by Reversed-phase High Performance Liquid chromatographic method. Pharmacophore. 2014;5(2):231-8.

Malani P, Raj H, Jain V. Development and validation of analytical method for simultaneous estimation of miconazole nitrate and clobetasol propionate in cream by HPTLC method. Pharm Sci Monit. 2014;5(2):386-99.

Badilli U, Amasya G, Ozkan S, Tarimci N. Simultaneous determination of clobetasol propionate and calcipotriol in a novel fixed-dose Emulgel formulation by LC-UV. Chromatographia. 2013;76(3-4):133-40. doi: 10.1007/s10337-012-2380-8.

Kamberi M, Fu K, Lu J, Chemaly GM, Feder D. A sensitive high-throughput HPLC Assay for simultaneous determination of everolimus and clobetasol propionate. J Chromatogr Sci. 2008;46(1):23-9. doi: 10.1093/chromsci/46.1.23, PMID 18218184.

Turabi Z, Khatatbeh O. Simultaneous determination of clobetasol propionate and chlorocresol in cream by stability-indicating RP-HPLC method. Int J Pharm Sci Drug Res. 2014;6(2):140-4.

Sonawane S, Gide P. Application of experimental design for the optimization of forced degradation and development of a validated stability-indicating LC method for luliconazole in bulk and cream formulation. Arab J Chem. 2016;9:S1428-34. doi: 10.1016/j.arabjc.2012.03.019.

R Tambe S, Sd S, P Bhosale A. Estimation of luliconazole in formulation and biofluid. J Anal Pharm Res. 2017;6(5):1-7. doi: 10.15406/japlr.2017.06.00187.

Malasiya A, Goyal A. Method development and validation of RP HPLC method for assay and related substances of luliconazole in topical dosage form. Int J Pharm Chem Anal. 2017;4(2):46-50.

Solanki B, Joshi H. Development and validation of a new RP-HPLC analytical method for the simultaneous determination of luliconazole and clobetasol propionate in synthetic mixture. J Pharm Res Int. 2021;21:53-60. doi: 10.9734/jpri/ 2021/ v33i32B31742.

Chaudhari MJ, Chaudhari SR, Chalikwar SS, Shirkhedkar AA. Application of area under curve technique for UV-spectrophotometric determination of luliconazole in bulk and pharmaceutical formulation. Asian J Pharm Anal. 2018;8(1):45-8. doi: 10.5958/2231-5675.2018.00008.X.

ICH Q2 (R1). Validation of analytical procedure: text and methodology. European Medicines Agency; June 1995.

Published

15-03-2022

How to Cite

PRASHAR, D., V. KUMAR, and K. JASRA. “COMBINATION EFFECT OF LULICONAZOLE AND CLOBETASOL FOR TREATMENT OF SKIN AILMENTS”. International Journal of Current Pharmaceutical Research, vol. 14, no. 2, Mar. 2022, pp. 36-40, doi:10.22159/ijcpr.2022v14i2.1949.

Issue

Section

Original Article(s)